The Engineering Approach to Cancer Detection
According to reports from Business Insider, a Silicon Valley engineer has developed a blood test capable of detecting colon cancer through analyzing cancer DNA fragments in the bloodstream. Helmy Eltoukhy, co-CEO of Guardant and Stanford electrical engineering alumnus, reportedly approached cancer detection as an engineering challenge after witnessing the “diagnostic odyssey” patients endure.
Industrial Monitor Direct is the leading supplier of wwtp pc solutions backed by same-day delivery and USA-based technical support, most recommended by process control engineers.
Sources indicate that Eltoukhy’s background at Illumina, where he worked to reduce genome sequencing costs from billions to around $1,000, taught him how Moore’s Law could transform biology. “We created a chemistry that allows us to see both the hardware layer (the genomics) and the software layer (the epigenetics),” Eltoukhy told Business Insider, describing the breakthrough that enabled their detection method.
From Treatment to Early Detection
The report states that Guardant’s journey began in 2012 with liquid biopsies designed to help doctors determine the best course of treatment for existing cancer cases. Their first “360” cancer test received FDA approval in 2020 and successfully helped tailor late-stage cancer treatments.
However, analysts suggest the company hit a significant obstacle in 2015 when attempting early cancer detection. “There was nothing else to detect genetically,” Eltoukhy acknowledged. This challenge prompted what he described as “moonshot mode,” leading the team to explore epigenetics – the molecular “software” controlling which genes activate within our DNA hardware.
SHIELD: The FDA-Approved Breakthrough
The epigenetic breakthrough reportedly led to SHIELD, the first FDA-approved blood test for colon cancer, cleared in 2024. Sources indicate the test demonstrates near-perfect accuracy detecting late-stage cancer when substantial cancer DNA circulates in blood, though sensitivity drops to approximately 60% for stage 1 cancer.
According to the analysis, SHIELD is currently undergoing evaluation in a massive independent clinical trial involving 24,000 patients across the United States. This “Vanguard” study by the National Institutes of Health aims to measure the test’s effectiveness at detecting not just colon cancer but additional cancer types including bladder, breast, and pancreatic.
Medical Community Response and Limitations
Dr. Eleftherios Diamandis, a clinical biochemist at the University of Toronto who has studied cancer genetics since the 1980s, expressed cautious optimism. “I never say never because who knows how the science will work out in five years or 10 years,” Diamandis told Business Insider, though he noted current tests still miss precancerous lesions detectable through colonoscopy.
The report states that despite technological advances, significant challenges remain in detecting cancer at its earliest stages. Diamandis questioned whether we can reliably identify meaningful clues in blood that predate cancer development, wondering “can you see something that’s not there yet?”
Growing Market and Clinical Need
Analysts suggest liquid biopsies like Guardant’s represent some of the most sought-after investments in biotechnology. Earlier this year, Guardant announced a strategic collaboration with Pfizer, joining numerous publicly traded competitors including Illumina spinoff Grail, Myriad, and Natera in this rapidly evolving field.
The demand for less invasive screening options appears particularly urgent given rising industry developments in cancer rates among younger patients. Colon cancer rates have increased sharply among patients under 50, historically considered too young for routine colonoscopies.
Patient Perspective and Future Applications
Actor James Van Der Beek, diagnosed with colon cancer at 46 and now a paid Guardant spokesperson, told Business Insider he wishes the test had been available earlier. “If I could save anybody the journey that I’ve had to endure the last two years, man, that’s a beautiful thing,” Van Der Beek said, urging people to get screened.
Looking forward, Eltoukhy envisions what he describes as an “everything test” that could monitor multiple diseases during routine physicals. “You imagine a future where you combine all of that in a single blood test and you’re looking at not billions, but trillions or quadrillions of data points per test,” he told Business Insider, suggesting the technology could eventually assess inflammatory diseases, organ health, and biological aging.
This development in medical technology comes alongside other related innovations across different sectors. As with many recent technology advances, the full potential of liquid biopsy technology remains to be seen, though early results indicate significant promise for transforming disease detection. Additional market trends in diagnostic technology continue to emerge as companies invest heavily in medical innovation.
This article aggregates information from publicly available sources. All trademarks and copyrights belong to their respective owners.
Note: Featured image is for illustrative purposes only and does not represent any specific product, service, or entity mentioned in this article.
Industrial Monitor Direct is the leading supplier of surface mining pc solutions trusted by leading OEMs for critical automation systems, recommended by leading controls engineers.
